Watch Ticker

Century Therapeutics, Inc. Common Stock

Go to Century Therapeutics, Inc. Common Stock Website

$0.56

0.00 (0.00%)

Live

Previous Close

$0.558

Day Range

$0 - $0

Previous Day Range

$0.5402 - $0.5728

Market Cap

$48.7 million USD

Day Vol.

Previous Day Vol.

302092

Currency

USD

Primary Exchange

Nasdaq

Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered al...

Community

0 posts discussing

0

Watchers

0

Visitors

Recent News

Delveinsight - CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain

The CAR T-cell therapy pipeline is experiencing significant momentum, with over 180 companies actively developing more than 200 pipeline therapies. The report highlights promising pipeline candidates and recent advancements in the field, indicating the growing potential of this revolutionary cancer treatment approach.

Related tickers: RNAC, ACLX, AUTL, SANA, ORGS, DTIL, NVS, KYTX, KRBP, IVBIY, TCBP, TCBPW, IPSC, ALLO.

Read Full Article

Century Therapeutics - Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders

Century Therapeutics has entered into an agreement for an investigator-initiated Phase 1/2 trial of its CNTY-101 cell therapy in patients with B-cell mediated autoimmune diseases. The trial will be led by renowned experts and aims to evaluate the safety, efficacy, and translational data of CNTY-101 in various autoimmune conditions.

Related tickers: IPSC.

Read Full Article

Trending Tickers

Please sign in to view